

% Activated T cells
(CFSElo, CD25+)
60.0
50.0
40.0
30.0
20.0
10.0
0.0
No Rx
PHA 1 ug/ml
OKT3 1 ug/ml
BC3 1 ug/ml
IgG2a 1 ug/ml
OKT3 N297A 10 ug/ml
1 ug/ml
0.1 ug/ml
OKT3 IgG1AA 10 ug/ml
1 ug/ml
0.1 ug/ml
OKT3 IgG2AA 10 ug/ml
1 ug/ml
0.1 ug/ml
OKT3 IgG4AA 10 ug/ml
1 ug/ml
0.1 ug/ml
OKT3 HM1 10 ug/ml
1 ug/ml
0.1 ug/ml
Nuvion FL 10 ug/ml
1 ug/ml
0.1 ug/ml
OKT3 ala-ala FL 10 ug/ml
1 ug/ml
0.1 ug/ml

Fig. 1



% Activated T cells
(CFSElo, CD25+)
60
50
40
30
20
10
0
MLR
Responder Only
IgG2a
OKT3 mAb 10ug/mL
OKT3ala-ala
BC3 mAb
BC3 N297A SMIP
BC3 IgG1AA SMIP
BC3 IgG2AA SMIP
BC3 IgG4AA SMIP
Molar equivalents of 10ug/mL, 1ug/mL, 0.1ug/mL, 0.01ug/mL of mAb were tested

Fig. 2



Activated T cells
(CFSElo, CD25+)
60.00%
50.00%
40.00%
30.00%
20.00%
10.00%
0.00%
Responder Only
MLR
Ms IgG2b
BC3 mAb
OKT3ala-ala
BC3 N297A SMIP
BC3 HM1 SMIP
BC3 ΔCH2 SMIP
OKT3 N297A SMIP
OKT3 HM1 SMIP
OKT3 ΔCH2 SMIP
Molar equivalents of 10ug/mL, 1ug/mL, 0.1ug/mL of mAb were tested

Fig. 3



% T Cell Activation
(CFSElo, CD25+)
0
2
4
6
8
10
12
14
16
18
Responder (No TT)
Tetanus Toxoid 1ug/mL
IgG Control 10ug/mL
BC3 mAb
BC3 N297A SMIP
BC3 IgG1AA SMIP
BC3 IgG2AA SMIP
BC3 IgG4AA SMIP
BC3 HM1 SMIP
Molar equivalents of 10ug/mL, 1ug/mL, 0.1ug/mL of mAb were tested

Fig. 4



Day 4
TCR
CD3

Fig. 5B



Day 0
TCR
CD3
OKT3 mAb
OKT3 N297A SMIP
OKT3 IgG2AA SMIP
OKT3 IgG4AA SMIP

Fig.5A





Fig. 6B



OKT3 IgG1AA SMIP

OKT3 HM1

Fig. 6A



untreated
OKT3 mAb
BC3 mAb
OKT3 + anti-IgG
BC3 + anti-IgG
IgG + anti-IgG
OKT3 N297A
OKT3 IgG1AA
OKT3IgG2AA
OKT3IgG4AA
Change in Fluorescence
0
10
20
30
40
50
60
70
80
0
100
200
300
400
500
600
700
800
Time (sec)

Fig. 7





Fig. 8B



14 Analytes Analyzed

Fig. 8A



% Activated T cells
(CFSElo, CD25hi)
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
R only
S only
R:S
1 ug/ml
1 ug/ml
10 ug/ml
1 ug/ml
10 ug/ml
1 ug/ml
0.1 ug/ml
control
2C11 mAb
H57 mAb
2C11 Mu null SMIP
H57 Mu null SMIP
R-Balb/C S-B6

Fig. 9




Fig. 10A




Fig. 10B



IL-6
pg/ml
3000
2500
2000
1500
1000
500
0
2HR
24HR
72HR
PBS
IgG2a 250ug
H57 mAb 5ug
H57 Nuli2 7.3ug
37ug
75ug
185ug

Fig. 11A



IL-4
Serum Conc (pg/ml)
800
700
600
500
400
300
200
100
0
2HR
24HR
72HR
PBS
IgG2a 250ug
H57 mAb 5ug
H57 Nuil2 7.3ug
37ug
75ug
185ug

Fig. 11B



Spleen
Day 1
Day 3
%SMIP+ T cells
0
20
40
60
80
100
PBS
IgG2a 250ug
H57 NuIL2 7.3ug
37ug
75ug
185ug

Fig. 12



% of Initial Body Weight
+/- std
115.0
110.0
105.0
100.0
95.0
90.0
85.0
80.0
75.0
0
2
4
6
8
10
12
14
Days
Naive Recipient
PBS
DEX
IgG Control
H57 Null2 SMIP

Fig. 13




Fig. 14A

Fig. 14B




Fig. 14C



Donor Lymphocyte: Host Lymphocyte Ratio
(% H2b: %H2b/d)
10
8
6
4
2
0
No Cell Transfer
PBS
IgG2a
DEX
H57 Nu/l2 SMIP
Donor Cell Transfer + Indicated

Fig. 15

231	A P E L L G G P S V F L F P P K P K D T	Human IgG1 CH2
231	A P P V A G - P S V F L F P P K P K D T	Human IgG2 CH2
231	A P E F L G G P S V F L F P P K P K D T	Human IgG4 CH2
231	A P D L L G G P S V F I F P P K I K D V	Mouse IGHG2c CH2
251	L M I S R T P E V T C V V V D V S H E D	Human IgG1 CH2
251	L M I S R T P E V T C V V V D V S H E D	Human IgG2 CH2
251	L M I S R T P E V T C V V V D V S Q E D	Human IgG4 CH2
251	L M I S L S P M V T C V V V D V S E D D	Mouse IGHG2c CH2
271	P E V K F N W Y V D G V E V H N A K T K	Human IgG1 CH2
271	P E V Q F N W Y V D G M E V H N A K T K	Human IgG2 CH2
271	P E V Q F N W Y V D G V E V H N A K T K	Human IgG4 CH2
271	P D V Q I S W F V N N V E V H T A Q T Q	Mouse IGHG2c CH2
291	P R E E Q Y **N** S T Y R V V S V L T V L H	Human IgG1 CH2
291	P R E E Q F **N** S T F R V V S V L T V V H	Human IgG2 CH2
291	P R E E Q F **N** S T Y R V V S V L T V L H	Human IgG4 CH2
291	T H R E D Y **N** S T L R V V S A L P I Q H	Mouse IGHG2c CH2
311	Q D W L N G K E Y K C K V S N K A L P A	Human IgG1 CH2
311	Q D W L N G K E Y K C K V S N K G L P A	Human IgG2 CH2
311	Q D W L N G K E Y K C K V S N K G L P S	Human IgG4 CH2
311	Q D W M S G K E F K C K V N N R A L P S	Mouse IGHG2c CH2
331	P I E K T I S K A K	Human IgG1 CH2
331	P I E K T I S K T K	Human IgG2 CH2
331	S I E K T I S K A K	Human IgG4 CH2
331	P I E K T I S K P R	Mouse IGHG2c CH2

Fig. 16



MLR Reaction day7
Activated T cells
(CSFEIo CD25+)
0
5
10
15
20
25
30
35
40
45
50
R+S
R only
S only
10 µg/ml mulgG2b
7.3 µg/ml Control SMIP
BC3-mAb
BC3-N297A
100%POI
CRIS7-N297A
~50%POI
10, 1, 0.1 µg/ml Ab OR
7.3, 0.73, .073 µg/ml SMIP

Fig. 17



Day 2
Day 0
Cris7 mAb
1.0 ug/ml
Cris-7 IgG1-N297A
0.73 ug/ml
TCR
Comp-FITC-A
Comp-PE-A
day 2 Cris7 mAb 1ug/ml
day 0 Cris7 mAb 1ug/ml
0.12
85.65
0.02
14.21
0.03
10.72
0.06
89.19
86.30
8.36
0.09
5.25
85.97
12.44
0.00
1.59

Fig. 18



Linker 87
Linker 118
Linker 122
Linker 120
Linker 117
Linker 119
Linker 115
Linker 116
Chimeric mAb BC3
mAb BC3
scFv BC3
Human xlink only
Mouse xlink only
Cells only
RFU
Time
0
5
10
15
20
25
30
35
40
45
50
55
60
65
0
250
500
750
1000
1250

Fig. 19



% of CFSE lo CD25 hi cells
CD5+ cells
0
10
20
30
40
50
60
70
80
Control SMIP 7.3ug/ml
[232] 7.37ug/ml
[232] 0.73ug/ml
[232] 0.073ug/ml
[234] 7.3ug/ml
[234] 0.73ug/ml
[236] 7.3ug/ml
[236] 0.73ug/ml
[236] 0.073ug/ml
[238] 7.3ug/ml
[238] 0.73ug/ml
[238] 0.073ug/ml
[240] 7.3ug/ml
[240] 0.73ug/ml
[240] 0.073ug/ml
[91] 7.3ug/ml
[91] 0.73ug/ml
[91] 0.073ug/ml
OKT3 FL 10ug/ml
OKT3 FL 1ug/ml
OKT3 FL 0.1ug/ml
OKT3 mAb 10ugml.fcs
OKT3 mAb 1ug/ml
OKT3 mAb 0.1ug/ml
responder only

Fig. 20



BC3 hinge variant MLR blockade assay
■ CD5+ ■ CD4+ □ CD8+
%CFSElo CD25hi
90
80
70
60
50
40
30
20
100
No Rx
Control SMIP
0.073mg/ml
0.73mg/ml
7.3mg/ml
BC3 SMIP N297A
IgA2 BC3
IgD BC3
IgECH2 BC3
UBA BC3
hulg1 BC3
MLR
Cntl

Fig. 21



MLR blockade assay % activated cells
% live T cells
80
70
60
50
40
30
20
10
0
responder only
Cris7 ch 0.073ugml
Cris 7ch 0.73ugml
Cris 7ch 7.3ugml
Cri7 mAb 0.1ugml
Cris7 mAb 1ugml
Cris7 mAb 10ugml
BC3 SMIP 0.073ugml
BC3 SMIP 0.73ugml
BC3SMIP 7.3ugml
[298] 0.073ugml
[298] 0.73ugml
[298] 7.3ugml
[293] 0.073ugml
[293] 0.73ugml
[293] 7.3ugml
[297] 0.073ugml
[297] 0.73ugml
[297] 7.3ugml
[292] 0.073ugml
[292] 0.73ugml
[292] 7.3ugml
[295] 0.073ugml
[295] 0.73ugml
[295] 7.3ugml
[290] 0.073ugml
[290] 0.73ugml
[290] 7.3ugml
Control SMIP 7.3ugml
MLR only
G1-N297A
G2-AA-N297A
G4-AA-N297A

Fig. 22



%CSFE1o, CD25hi
250.00
200.00
150.00
100.00
50.00
0.00
7.3, 0.73 or .073 µg/ml SMIP; 10, 1 or 0.1 µg/ml of Ab
responder only.fcs
MLR only.fcs
Control SMIP
Parent mAb
Parent mAb
Parent mAb
HMI
IgG1-N297A
HMI
IgG4-AA-N297A
IgG2-AA-N297A
IgG1-N297A
HMI
IgG4-AA-N297A
IgG2-AA-N297A
IgG1-N297A
Humanized Cris7 (VH3-VL1) SMIP
Humanized Cris7 (VH3-VL2) SMIP
Chimeric Cris7 SMIP

Fig. 23



Restimulation of PHA Activated T cells
CD5+ CD4+ CD8+
Gated Cells (% CSFElo-CD25Hi)
30
25
20
15
10
5
0
Control SMIP (7.3)
HuCris7 (VH3-VL1) (7.3) (0.73) IgG1-N297A
HuCris7 (VH3-VL2) (7.3) (0.73) IgG1-N297A
PHA
Sample

Fig. 24



IFNγ
con.(pg/ml)
400
350
300
250
200
150
100
50
0
d1
d3
Control
[290]
[290]
[295]
[295]
[292]
[292]
[297]
[297]
[293]
[293]
[298]
[298]
BC3 SMIP
BC3 SMIP
BC3 mAb
BC3 mAb
[265]
[265]
parent
Parent
CFSE
PHA
Nuvion FL
Nuvion FL
Nuvion FL

Fig. 25A



IL-17
d1
d3
con.(pg/ml)
350
300
250
200
150
100
50
0
Control
[290]
[290]
[295]
[295]
[292]
[292]
[297]
[297]
[293]
[293]
[298]
[298]
BC3 SMIP
BC3 SMIP
BC3 mAb
BC3 mAb
[265]
[265]
parent
Parent
CFSE
PHA
Nuvion FL
Nuvion FL
Nuvion FL

Fig. 25B



d1
d2
d3
IFN gamma
pg/ml
200
150
100
50
0
PBMC only
0.1ug/ml
1ug/ml
10ug/ml
Cris7 mAb
1ug/ml
PHA only
7.3ug/ml
Cntl SMIP
0.073ug/ml
0.73ug/ml
7.3ug/ml
HuCris7 (VH3-VL2) IgG4-AA-N297A
0.073ug/ml
0.73ug/ml
7.3ug/ml
HuCris7 (VH3-VL1) IgG4-AA-N297A

Fig. 26A



IL-10
pg/ml
50
40
30
20
10
0
d1
d2
d3
HuCris7 (VH3-VL1) IgG4-AA-N297A
7.3ug/ml
0.73ug/ml
0.073ug/ml
HuCris7 (VH3-VL2) IgG4-AA-N297A
7.3ug/ml
0.73ug/ml
0.073ug/ml
Cntl SMIP
7.3ug/ml
PHA only
1ug/ml
Cris7 mAb
10ug/ml
1ug/ml
0.1ug/ml
PBMC only

Fig. 26B



IL-1B
pg/ml
0
1
2
3
4
5
6
7
8
9
d1
d2
d3
7.3ug/ml
0.73ug/ml
0.073ug/ml
7.3ug/ml
0.73ug/ml
0.073ug/ml
7.3ug/ml
1ug/ml
10ug/ml
1ug/ml
0.1ug/ml
HuCris7 (VH3-VL1) IgG4-AA-N297A
HuCris7 (VH3-VL2) IgG4-AA-N297A
Cntl SMIP
PHA only
Cris7 mAb
PBMC only

Fig. 26C



IL-17
pg/ml
0
1
2
3
4
5
6
7
8
9
10
d1
d2
d3
HuCris7 (VH3-VL1) IgG4-AA-N297A
7.3ug/ml
0.73ug/ml
0.073ug/ml
HuCris7 (VH3-VL2) IgG4-AA-N297A
7.3ug/ml
0.73ug/ml
0.073ug/ml
Cntl SMIP
7.3ug/ml
PHA only
1ug/ml
Cris7 mAb
10ug/ml
1ug/ml
0.1ug/ml
PBMC only

Fig. 26D



IL-4
d1
d2
d3
pg/ml
20
15
10
5
0
7.3ug/ml
0.73ug/ml
0.073ug/ml
HuCris7 (VH3-VL1) IgG4-AA-N297A
7.3ug/ml
0.73ug/ml
0.073ug/ml
HuCris7 (VH3-VL2) IgG4-AA-N297A
7.3ug/ml
Cntl SMIP
1ug/ml
PHA only
10ug/ml
1ug/ml
0.1ug/ml
Cris7 mAb
PBMC only

Fig. 26E



TNF-a
d1
d2
d3
pg/ml
PBMC only
Cris7 mAb
0.1ug/ml
1ug/ml
10ug/ml
PHA only
1ug/ml
Cntl SMIP
7.3ug/ml
HuCris7 (VH3-VL2) IgG4-AA-
0.073ug/ml
0.73ug/ml
7.3ug/ml
HuCris7 (VH3-VL1) IgG4-AA-
0.073ug/ml
0.73ug/ml
7.3ug/ml

Fig. 26F



IL-6
pg/ml
0
10
20
30
40
50
d1
d2
d3
HuCris7 (VH3-VL1) IgG4-AA-N297A
7.3ug/ml
0.73ug/ml
0.073ug/ml
HuCris7 (VH3-VL2) IgG4-AA-N297A
7.3ug/ml
0.73ug/ml
0.073ug/ml
Cntl SMIP
7.3ug/ml
PHA only
1ug/ml
Cris7 mAb
10ug/ml
1ug/ml
0.1ug/ml
PBMC only

Fig. 26G



IL-2
pg/ml
0
1
2
3
4
5
6
7
8
9
10
d1
d2
d3
7.3ug/ml
0.73ug/ml
0.073ug/ml
HuCris7 (VH3-VL1) IgG4-AA-N297A
7.3ug/ml
0.73ug/ml
0.073ug/ml
HuCris7 (VH3-VL2) IgG4-AA-N297A
7.3ug/ml
Cntl SMIP
1ug/ml
PHA only
10ug/ml
1ug/ml
0.1ug/ml
Cris7 mAb
PBMC only

Fig. 26H



Percent of Initial Body Weight
105
100
95
90
85
80
0
1
2
3
4
IgG2a
H57 Null2
H57 HM2
H57 1/2 Null
H57 mAb

Fig. 27



● 2hr Bleed (peripheral blood)
Cells / ml
4.0×10^6
3.0×10^6
2.0×10^6
1.0×10^6
0
IgG2a
H57 Null2
H57 1/2 Null
H57 HM2
H57 mAb

Fig. 28




● 72hr Harvest
Cells / ml
4.0×10^6
3.0×10^6
2.0×10^6
1.0×10^6
0
IgG2a
H57 Null2
H57 1/2 Null
H57 HM2
H57 mAb

Fig. 29



* p < 0.05 vs. IgG2a, H57 Null2, H57 1/2 Null and H57 HM2

Fig. 30A



IL-2 (24hr)
pg/mL
2500
2000
1500
50
40
30
20
10
0
H57 mAb
IgG2a
H57 1/2 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent

Fig. 30B



IL-2 (72hr)
pg/mL
2500
2000
1500
150
100
50
0
H57 mAb
IgG2a
H57 1/2 Null
H57 Null2
H57 HM2
5 ug
300 ug molar equivalent

Fig. 30C



IL-10 (2hr)
pg/mL
800
600
400
200
0
*
*
H57 mAb
IgG2a
H57 12 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent
p < 0.05 vs. IgG2a, H57 Null2, H57 1/2 Null and H57 HM2

Fig. 31A



IL-10 (24hr)
pg/mL
800
600
400
200
100
0
H57 mAb
IgG2a
H57 1/2 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent

Fig. 31B




IL-10 (72hr)
pg/mL
800
600
400
200
100
0
H57 mAb
IgG2a
H57 12 Null
H57 Null2
H57 HM2
5 ug
300 ug molar equivalent

Fig. 31C



* p < 0.05 vs. IgG2a, H57 Null2, H57 1/2 Null and H57 HM2

Fig. 32A



IP-10 (24hr)
pg/mL
800
600
400
200
200
100
0
#
H57 mAb
IgG2a
H57 1/2 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent
# p < 0.05 vs. all other groups

Fig. 32B



IP-10 (72hr)
pg/mL
800
600
400
200
150
100
50
0
#
H57 mAb
IgG2a
H57 1P2 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent
# p < 0.05 vs. all other groups

Fig. 32C



TNFα (2hr)
pg/mL
50
40
30
20
10
0
*
*
H57 mAb
IgG2a
H57 1/2 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent
* p < 0.05 vs. IgG2a, H57 Null2, H57 1/2 Null and H57 HM2

Fig. 33A



TNFα (24hr)
pg/mL
50
40
10
0
H57 mAb
IgG2a
H57 1/2 Null
H57 Null 2
H57HM2
5 ug
300 ug molar equivalent

Fig. 33B



TNFα (72hr)
pg/mL
50
40
10
0
H57 mAb
IgG2a
H57 1/2 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent

Fig. 33C



IL-4 (2hr)
pg/mL
250
200
150
100
50
0
#
H57 mAb
IgG2a
H57 1/2 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent
# p < 0.05 vs. all other groups

Fig. 34A



IL-4 (24hr)
pg/mL
250
200
150
100
50
1.0
0.8
0.6
0.4
0.2
0.0
H57 mAb
IgG2a
H57 1/2 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent

Fig. 34B



IL-4 (72hr)
pg/mL
250
200
150
100
50
1.0
0.8
0.6
0.4
0.2
0.0
H57 mAb
IgG2a
H57 1/2 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent

Fig. 34C



MCP-1 (2hr)
pg/mL
6000
4000
2000
2000
1500
1000
500
0
#
H57 mAb
IgG2a
H57 1/2 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent
# p < 0.05 vs. all other groups

Fig. 35A



MCP-1 (24hr)
pg/mL
6000
5000
4000
3000
2000
1000
0
#
H57 mAb
IgG2a
H57 12 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent
# p < 0.05 vs. all other groups

Fig. 35B




MCP-1 (72hr)
pg/mL
6000
4000
2000
250
200
150
100
50
0
H57 mAb
IgG2a
H57 1/2 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent

Fig. 35C



** p < 0.05 vs. IgG2a, H57 Null 2, and H57 HM2

Fig. 36A



KC (24 hr)
pg/mL
3000
2000
1000
500
0
#
H57 mAb
IgG2a
H57 1/2 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent
# p < 0.05 vs. all other groups

Fig. 36B





KC (72hr)
pg/mL
300 0
200 0
100
50
0
H57 mAb
IgG2a
H57 1/2 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent

Fig. 36C



# $p < 0.05$ vs. all other groups

Fig. 37A



# $p < 0.05$ vs. all other groups

Fig. 37B



IL-17 (72hr)
pg/mL
100
80
60
15
10
5
0
H57 mAb
19G2a
H57 1/2 Null
H57 Null2
H57 HM2
5 ug
300 ug molar equivalent

Fig. 37C



IL-5 (2hr)
pg/mL
2000
1500
1000
25
20
15
10
5
0
H57 mAb
IgG2a
H57 12 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent

Fig. 38A



IL-5 (24 hr)
#
pg/mL
2000
1000
0
H57 mAb
IgG2a
H57 1/2 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent
# p < 0.05 vs. all other groups

Fig. 38B



IL-5 (72hr)
pg/mL
2000
1500
1000
30
20
10
0
H57 mAb
IgG2a
H57 1/2 Null
H57 Null 2
H57 HM2
5 ug
300 ug molar equivalent

Fig. 38C



Tru.pc.0148, PK Analysis of H57 HM2 Samples
Rsq=0.994 Rsq_adjusted=0.988 HL_Lambda_z=6.6515 (hr)
(3 points used in calculation)
Uniform Weighting
Observed
Predicted
Mean_Conc. (ug/mL)
100.0
10.0
1.0
0.1
0
5
10
15
20
25
30
Time (hr)

Fig. 39A



Tru.pc.0148, PK Analysis of H57 1/2 null Samples
Rsq=0.924 Rsq_adjusted=0.9087 HL_Lambda_z=40.7342 (hr)
(7 points used in calculation)
Uniform Weighting
Observed
Predicted
Mean_Conc. (ug/mL)
1000.0
100.0
10.0
1.0
0.1
0
50
100
150
200
250
300
350
Time (hr)

Fig. 39B



G-CSF
pg/mL
20000
15000
10000
5000
1000
800
600
400
200
0
15min
2hr
6hr
24hr
48hr
H57 HM2
H57 ½ Null

Fig. 40



IFNγ
pg/mL
2000
1500
1000
500
0
15min
2hr
6hr
24hr
48hr
H57 HM2
H57 ½ Null

Fig. 41



IL-2
pg/mL
2500
2000
1500
1000
500
0
15min
2hr
6hr
24hr
48hr
H57 HM2
H57 ½ Null

Fig. 42



IL-5
H57 HM2
H57 ½ Null
pg/mL
250
200
150
100
50
0
15min
2hr
6hr
24hr
48hr

Fig. 43



IL-6
H57 HM2
H57 ½ Null
pg/mL
4000
3000
2000
1000
0
15min
2hr
6hr
24hr
48hr

Fig. 44



IL-10
pg/mL
250
200
150
100
50
0
15min
2hr
6hr
24hr
48hr
H57 HM2
H57 ½ Null

Fig. 45



IL-17
pg/mL
200
150
100
50
0
15min
2hr
6hr
24hr
48hr
H57 HM2
H57 ½ Null

Fig. 46



IP-10
pg/mL
1500
1000
500
0
15min
2hr
6hr
24hr
48hr
H57 HM2
H57 ½ Null

Fig. 47



KC
H57 HM2
H57 ½ Null
15000
10000
5000
2000
1500
1000
500
0
pg/mL
15m in
2hr
6hr
24hr
48hr

Fig. 48



MCP-1
pg/mL
10000
7500
5000
1000
800
600
400
200
0
15min
2hr
6hr
24hr
48hr
H57 HM2
H57 ½ Null

Fig. 49



CD5+ CFSE-lo CD25-hi
160
140
120
100
80
60
40
20
0
R+S
%CD25=47%
Media
557 nuII
HER018
2C11
H57 Null2
(CHO)
H57 1/2null
(CHO)
Lot 1
H57 1/2null
(CHO)
Lot 2
H57 HM2
(CHO)
H57 1/2null
(293)
H57 HM2
(293)
H57 mAb
Mouse
IgG2a
100nM
33nM
11nM
3.7nM
1.2nM
0.4nM
0.1nM

Fig. 50



100nM
33nM
11nM
3.7nM
1.2nM
0.4nM
0.14nM
R+S = 54%
Mouse MLR
% CD5+ CD25+
120.00%
100.00%
80.00%
60.00%
40.00%
20.00%
0.00%
H57 Null2
H57 half-Null
H57 HM2
H57 mAb

Fig. 51



% CFSElo CD25hi
40.00%
35.00%
30.00%
25.00%
20.00%
15.00%
10.00%
5.00%
0.00%
ConA = 62%
1 nM
10 nM
100 nM
1000 nM
ConA (1ug/ml)
H57 Null2
H57 1/2 null Lot 1
H57 1/2 null Lot 2
H57 HM2
IgG2a
H57 mAb
2C11 mAb

Fig. 52